Washington Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Washington Capital Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-994	Closed	-$540K	–	138
2015 Q4	$540K	Hold	994	–	–	0.34%	90
2015 Q3	$462K	Sell	994 -167	-14%	-$89.7K	0.29%	93
2015 Q2	$592K	Hold	1,161	–	–	0.33%	93
2015 Q1	$524K	Hold	1,161	–	–	0.3%	92
2014 Q4	$476K	Hold	1,161	–	–	0.2%	102
2014 Q3	$419K	Hold	1,161	–	–	0.17%	107
2014 Q2	$328K	Hold	1,161	–	–	0.12%	136
2014 Q1	$349K	Hold	1,161	–	–	0.13%	127
2013 Q4	$320K	Sell	1,161 -64	-5%	-$18.4K	0.08%	159
2013 Q3	$383K	Sell	1,225 -516	-30%	-$136K	0.1%	151
2013 Q2	$392K	Buy	+1,741	New	+$405K	0.1%	166

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Washington Capital Management's REGN Position: Q1 2016 in Review

Washington Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q1 2016, closing a stake of 994 shares — an estimated $540K sold.

Washington Capital Management first reported a position in REGN in Q2 2013 and held it in 11 quarters. The position peaked at $592K in Q2 2015. 550 funds tracked by Wall St. Rank hold REGN as of Q1 2016.

Washington Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
Washington Capital Management sold 994 Regeneron Pharmaceuticals shares in Q1 2016, an estimated $540K.
Washington Capital Management first reported a position in Regeneron Pharmaceuticals in Q2 2013 and held it in 11 quarters.
Washington Capital Management's Regeneron Pharmaceuticals position peaked at $592K in Q2 2015.
550 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2016.

Based on Washington Capital Management's 13F filing for Q1 2016, filed 9 May 2016.